Key facts
- Notable investors include Future Planet Capital, UK Innovation & Science Seed Fund, Biotechnology and Biological Sciences Research Council, Accelerate@Babraham, London School of Hygiene & Tropical Medicine — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for ArkVax
- ·The full record, as it builds
Funding rounds
No funding rounds for ArkVax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ArkVax
Developer of a glycan-based vaccine technology intended to revolutionize animal vaccinology and combat antimicrobial resistance. The company's platform specializes in developing glycoconjugate vaccines through bacterial engineering, which involves genetically modifying bacterial cells to produce a sugar-based payload, enabling the livestock industry to reduce antibiotic use and safeguarding both animal and human health from zoonotic diseases.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 5
- Website
- arkvax.com/
- Ownership
- Privately Held (backing)
ArkVax doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ArkVax shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ArkVax in its N-PORT filings yet. We sweep new filings monthly.